Impact of Esaxerenone on Albuminuria and Proteinuria: An Evidence-Based Review

Abstract

This review critically examines the impact of esaxerenone, a novel non-steroidal mineralocorticoid receptor antagonist, on albuminuria and proteinuria in patients at risk for or suffering from chronic kidney disease (CKD) and diabetic nephropathy. Drawing from recent clinical trials and guideline updates, the article explores the underlying mechanisms, clinical outcomes, and practical implications of esaxerenone therapy, providing healthcare professionals with insights into its role in renal protection and cardiovascular risk mitigation.

Introduction

Chronic kidney disease (CKD) and diabetic nephropathy are significant global health challenges marked by progressive renal impairment and increased risk of cardiovascular events. Albuminuria and proteinuria, key clinical markers of kidney damage, predict not only renal but also cardiovascular morbidity and mortality. Therapeutic strategies targeting these markers are crucial for improving patient outcomes. Esaxerenone, a selective non-steroidal mineralocorticoid receptor antagonist (MRA), has emerged as a promising therapeutic option shown to reduce albuminuria and proteinuria, thereby potentially altering the course of CKD. This review synthesizes current evidence on esaxerenone’s efficacy, safety, and clinical relevance in the management of albuminuria and proteinuria.

Epidemiology / Disease Burden

The prevalence of CKD worldwide is estimated to be 9-13%, with diabetes and hypertension constituting the primary etiologies. Albuminuria and proteinuria affect approximately 30-40% of patients with diabetes and are associated with accelerated progression to end-stage kidney disease (ESKD) and cardiovascular complications. The burden of these conditions is particularly high in populations with poor access to healthcare, leading to increased morbidity, mortality, and healthcare costs. Early intervention targeting albuminuria and proteinuria is thus an important strategy in global CKD management.

Pathophysiology

Albuminuria and proteinuria arise from glomerular filtration barrier dysfunction, often due to systemic and intrarenal hemodynamic changes, inflammation, and oxidative stress. Mineralocorticoid receptors (MR) play a central role in mediating sodium retention, fibrosis, and inflammation. Overactivation of MR, particularly in the context of hyperglycemia and hypertension, leads to podocyte injury and glomerulosclerosis, contributing to urinary protein loss. The modulation of MR signaling is therefore a critical therapeutic target for attenuating kidney injury and its sequelae.

Risk Factors

Major risk factors for the development and progression of albuminuria and proteinuria include diabetes mellitus, hypertension, genetic predisposition, obesity, smoking, and prolonged use of nephrotoxic agents. Poor glycemic and blood pressure control are particularly important modifiable risk factors. Additionally, African and South Asian ethnicities are at higher risk, and age-related decline in renal function further exacerbates susceptibility, underscoring the need for targeted prevention and risk stratification.

Clinical Features

Patients with albuminuria or proteinuria may remain asymptomatic in early stages. As kidney damage progresses, clinical manifestations can include edema, hypertension, and signs of impaired renal function such as fatigue and electrolyte disturbances. Microalbuminuria (30–300 mg/g creatinine) is often the earliest detectable marker, while overt proteinuria (>300 mg/g) typically signals more advanced disease and portends a higher risk of ESKD and cardiovascular events.

Diagnosis

Diagnosis relies on quantitative measurement of urinary albumin excretion (e.g., albumin-to-creatinine ratio [ACR] or 24-hour urine protein). Routine screening is recommended for individuals with diabetes, hypertension, and other CKD risk factors. Serial measurements are vital for monitoring disease progression and therapeutic response. Additional workup includes assessment of renal function (eGFR), blood pressure, and evaluation for secondary causes of proteinuria as clinically indicated.

Treatment & Management

Optimal management of albuminuria and proteinuria focuses on rigorous blood pressure and glycemic control, renin-angiotensin-aldosterone system (RAAS) blockade (ACE inhibitors or ARBs), and lifestyle modification. Sodium restriction, weight control, and smoking cessation are foundational. In patients with persistent proteinuria despite standard therapy, mineralocorticoid receptor antagonists have demonstrated incremental benefit, but classical agents such as spironolactone and eplerenone are limited by hyperkalemia and hormonal side effects.

Recent Advances / Emerging Therapies

Esaxerenone represents a significant advance in the MRA class, offering high MR selectivity and minimal off-target hormonal effects compared to earlier agents. Clinical trials, including the ESAX-DN and ESAX-HTN studies, have shown that esaxerenone significantly reduces albuminuria in patients with diabetic nephropathy and hypertension, both as monotherapy and as add-on to RAAS inhibitors. Mechanistically, esaxerenone attenuates renal inflammation and fibrosis while preserving electrolyte homeostasis, translating to improved renal and cardiovascular outcomes. Importantly, the incidence of hyperkalemia appears lower than with traditional MRAs, enhancing its clinical utility.

Guideline Recommendations

Recent guidelines from nephrology and diabetes societies now recognize non-steroidal MRAs like esaxerenone as a therapeutic consideration for patients with persistent albuminuria or proteinuria despite optimized RAAS blockade. The Japanese Society of Nephrology and other expert panels recommend esaxerenone, particularly for patients at high risk of CKD progression, while emphasizing individualized risk-benefit assessment and regular monitoring of serum potassium and renal function.

Conclusion

Esaxerenone offers a novel, effective, and comparatively safe option for reducing albuminuria and proteinuria in high-risk CKD populations. Its favorable pharmacological profile, supported by robust clinical trial evidence, positions it as a valuable adjunct or alternative to traditional therapies. Ongoing surveillance for hyperkalemia and renal function is essential. Further studies are warranted to elucidate long-term renoprotective and cardioprotective effects, optimal patient selection, and comparative efficacy against other emerging agents. Integration of esaxerenone into clinical practice represents a promising advancement in the multidisciplinary management of CKD and diabetic nephropathy.